Last reviewed · How we verify
pemetrexed, cisplatin and CBP501 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
pemetrexed, cisplatin and CBP501 (pemetrexed, cisplatin and CBP501) — CanBas Co. Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| pemetrexed, cisplatin and CBP501 TARGET | pemetrexed, cisplatin and CBP501 | CanBas Co. Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- pemetrexed, cisplatin and CBP501 CI watch — RSS
- pemetrexed, cisplatin and CBP501 CI watch — Atom
- pemetrexed, cisplatin and CBP501 CI watch — JSON
- pemetrexed, cisplatin and CBP501 alone — RSS
Cite this brief
Drug Landscape (2026). pemetrexed, cisplatin and CBP501 — Competitive Intelligence Brief. https://druglandscape.com/ci/pemetrexed-cisplatin-and-cbp501. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab